Research Topics
| Andrew J StephensonSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomyAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Nat Clin Pract Urol 1:90-6. 2004..To be successful, salvage EBRT should be administered at the earliest evidence of recurrent disease, once a rising PSA trend as been confirmed...- Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definitionAndrew J Stephenson
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:3973-8. 2006..Ten definitions of BCR were evaluated to identify the one that best explains metastatic progression... - Perspectives on the natural history of recurrent prostate cancer after radical prostatectomy, based on the response to salvage radiotherapyAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
BJU Int 94:1210-2. 2004 
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomyAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Natl Cancer Inst 98:715-7. 2006..Thus, a new preoperative nomogram provides robust predictions of prostate cancer recurrence up to 10 years after radical prostatectomy...- Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomyAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Clin Oncol 23:7005-12. 2005..Unique to predictive models, the nomogram predictions can be adjusted for the disease-free interval that a patient has achieved after RP... - Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapyFernando J Bianco
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Int J Radiat Oncol Biol Phys 62:448-53. 2005..Long-term control of locally recurrent prostate cancer after definitive RT is possible when salvage RP is performed early in the course of recurrent disease... - Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasionAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers and Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 174:557-60; discussion 560. 2005..After primary RPLND and selective adjuvant chemotherapy late recurrence is distinctly uncommon and long-term cancer control is anticipated in essentially all patients... - Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancerAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 25:5597-602. 2007..3). CONCLUSION Patient selection factors have significantly improved the outcome of patients with CS IIA and IIB NSGCT without substantially increasing the proportion of patients exposed to chemotherapy... - Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapyAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 23:8198-203. 2005..Salvage RP may favorably alter the natural history of biochemical recurrence after radiation therapy, but it must be instituted early in the course of recurrent disease to be effective... - Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogramRyan K Berglund
Division of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Urology 73:1098-103. 2009..5 ng/mL had outcomes different than predicted by a validated preoperative nomogram... - Salvage therapy for locally recurrent prostate cancer after external beam radiotherapyAndrew J Stephenson
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Treat Options Oncol 5:357-65. 2004..A long-term cure is possible for patients with locally recurrent prostate cancer after radiation therapy. Local salvage therapy must be instituted early to be successful in the course of progressive disease... - Salvage radiotherapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
JAMA 291:1325-32. 2004..Selected patients with high-grade disease and/or a rapid PSADT who were previously thought to be destined to develop progressive metastatic disease may achieve a durable response to salvage radiotherapy... - Recovery of erectile function after salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapyTimothy A Masterson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Urology 66:623-6. 2005..Peripheral nerve grafts did not appear to influence the recovery of erections in this patient population... - Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcomeAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 23:2781-8. 2005..For patients with normal STM and CS I to IIA disease, the low rate of systemic progression and 22% incidence of retroperitoneal teratoma supports RPLND as the preferred primary intervention... - Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapyAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 172:2239-43. 2004..The acceptable morbidity profile of salvage RP following EBRT and transperineal IRT should persuade more physicians to consider patients for this potentially curative procedure... - Management of patients with low-stage nonseminomatous germ cell testicular cancerAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Treat Options Oncol 6:367-77. 2005.... - Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancerAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
J Urol 176:1996-9; discussion 1999. 2006.... - Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomyAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 104:290-8. 2005.... 
Laparoscopic radical cystectomy for muscle-invasive bladder cancer: pathological and oncological outcomesAndrew J Stephenson
Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195 0001, USA
BJU Int 102:1296-301. 2008..Randomized trials are necessary to determine if the results achieved with LRC are equivalent to those of ORC...- Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumorAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 171:1474-7. 2004..In a cohort of patients who underwent exploratory laparotomy for unsuspected metastatic GCT we determined the impact of this surgery on morbidity, therapeutic delay and cancer therapy... - A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancerEdouard J Trabulsi
Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
Urology 72:1298-302; discussion 1302-4. 2008..We studied a group of patients undergoing ART by comparing them with a matched control group undergoing SRT after biochemical failure... - Who should be included in a clinical trial of screening for bladder cancer?: a decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening TrialAndrew J Vickers
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 119:143-9. 2013..Data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial were used and simple decision analytic techniques were applied to compare different eligibility criteria for a screening trial... - The role of retroperitoneal lymph node dissection in the management of testicular cancerAndrew J Stephenson
Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Urol Oncol 22:225-33; discussion 234-5. 2004..This article reviews the role of RPLND in the management of patients with NSGCT at all stages and its role in advanced seminoma... - Nomograms for prostate cancerAndrew J Stephenson
Section of Urologic Oncology, Glickman Urological Institute, Lerner College of Medicine, Cleveland, OH, USA
BJU Int 98:39-46. 2006 - Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomyAndrew J Stephenson
Division of Urology, McGill University, , , Canada
J Urol 172:58-62. 2004..The higher risk of abdominal relapse in patients with pT3A-B indicates that they should receive surveillance abdominal imaging. We recommend abdominal computerized tomography 6, 12, 24 and 36 months postoperatively... - Re: Zhao et al.: External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment Score (Urology 2008;72:396-400)Andrew J Stephenson
Urology 72:719-20. 2008 - Prostate cancer volume at biopsy predicts clinically significant upgradingFei Dong
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
J Urol 179:896-900; discussion 900. 2008..We identified clinical and pathological parameters that predict pathological upgrading in this population... - Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinationsPhillip L Ross
Division of Urology, McGill University, Montreal, Quebec, Canada
Urology 64:323-8. 2004..CONCLUSIONS: In untreated patients with localized prostate cancer, the PSADT varies considerably depending on the interval evaluated... - Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomyAndrew J Stephenson
Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
J Clin Oncol 25:2035-41. 2007..We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence... - Management of clinical stage I nonseminomatous germ cell testicular cancerToni K Choueiri
Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
Urol Clin North Am 34:137-48; abstract viii. 2007..For patients at high risk for relapse and who are not candidates for surveillance, we believe the evidence supports RPLND over primary chemotherapy... - Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapyMatthew N Simmons
Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue A100, Cleveland, OH 44195, USA
Eur Urol 51:1175-84. 2007..While a rising PSA level universally antedates metastatic progression and prostate cancer-specific mortality (PCSM), it is not a surrogate for these endpoints. Thus, the management of patients with BCR is controversial... - Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancerAndrew J Stephenson
Department of Surgery (Urology, McGill University, Montreal, Ontario, Canada
Urology 59:652-6. 2002..CONCLUSIONS: A PSADT of less than 120 months correlates with disease progression. However, its clinical utility remains limited to identify patients at risk of disease progression reliably... - Screening for urologic malignancies in primary care: pros, cons, and recommendationsAndrew J Stephenson
Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
Cleve Clin J Med 74:S6-14. 2007.... - Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practiceFei Dong
School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
J Urol 180:150-4; discussion 154. 2008..In patients referred for biopsy following community screening we validated the Kattan and Steyerberg nomograms for predicting indolent disease in a contemporary urological practice... - Systems pathology and predicting outcome after radical prostatectomyEric A Klein
J Clin Oncol 26:3916-7. 2008 - Gene expression profiling predicts clinical outcome of prostate cancerGennadi V Glinsky
Sidney Kimmel Cancer Center, San Diego, California 92121, USA
J Clin Invest 113:913-23. 2004....